Lyfgenia
Payments companies reported to CMS as associated with Lyfgenia. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lyfgenia, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lyfgenia
These are the largest totals companies reported as associated with Lyfgenia. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Andrew Dietz | Los Angeles, CA | Pediatric Hematology-Oncology | $87,750.00 |
| John Agwunobi | Torrance, CA | $32,500.00 | |
| Daniel Loes | Roseville, MN | Diagnostic Radiology | $12,052.50 |
| Robert Lindsley | Boston, MA | Medical Oncology | $8,160.00 |
| John Levine | New York, NY | Pediatric Hematology-Oncology | $7,820.00 |
| Stacey Rifkin-Zenenberg | Hackensack, NJ | Hospice and Palliative Medicine (Pediatrics) | $6,573.44 |
| Robert Hasserjian | Boston, MA | Hematology (Pathology) | $6,300.00 |
| Sonali Chaudhury | Chicago, IL | Pediatric Hematology-Oncology | $5,906.59 |
| Monica Bhatia | New York, NY | Pediatric Hematology-Oncology | $5,599.35 |
| Tami John | Palo Alto, CA | Pediatric Hematology-Oncology | $5,437.60 |
Prescribed Lyfgenia?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.